SCHEMBL358468

SCHEMBL358468

CCCCCCCCCCCCCC(=O)NCCCC[C@H](N)C(=O)O

nearest known ligand 0.74

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
NOD1 Q9Y239 6/20 0.74
CASP2 P42575 1/20 0.57
GNAI3 P08754 1/20 0.56
GNAO1 P09471 1/20 0.56
GNAI1 P63096 1/20 0.56
FAAH O00519 4/20 0.55
DPP7 Q9UHL4 1/20 0.55
EPHX2 P34913 3/20 0.55
NAAA Q02083 1/20 0.54
SLC6A5 Q9Y345 2/20 0.54
DNM1 Q05193 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31734852 1.00 NOD1 (0.74) NOD1CASP2GNAI3GNAO1GNAI1
SCHEMBL31358862 1.00 NOD1 (0.74) NOD1CASP2GNAI3GNAO1GNAI1
SCHEMBL15986104 1.00 NOD1 (0.74) NOD1CASP2GNAI3GNAO1GNAI1
SCHEMBL31711351 1.00 NOD1 (0.74) NOD1CASP2GNAI3GNAO1GNAI1
SCHEMBL13855547 1.00 NOD1 (0.74) NOD1CASP2GNAI3GNAO1GNAI1
SCHEMBL17392871 1.00 NOD1 (0.74) NOD1CASP2GNAI3GNAO1GNAI1
SCHEMBL1243678 1.00 NOD1 (0.74) NOD1CASP2GNAI3GNAO1GNAI1
SCHEMBL308741 1.00 NOD1 (0.74) NOD1CASP2GNAI3GNAO1GNAI1
SCHEMBL2386271 1.00 NOD1 (0.74) NOD1CASP2GNAI3GNAO1GNAI1
SCHEMBL20162089 1.00 NOD1 (0.74) NOD1CASP2GNAI3GNAO1GNAI1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 216 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017064718-A1 METHODS AND KITS FOR DETERMINING DEACYLASE ACTIVITY The National Institute for Biotechnology in the Negev Ltd. (IL) 2017-04-20 WO claimed
EP-4684030-A2 METHOD OF DEPROTECTING AT LEAST ONE D-AMINO ACID AND/OR D-AMINO ACID DERIVATIVE PROTECTED FUNCTIONAL GROUP Martin-Luther-Universität Halle-Wittenberg (DE) 2026-01-28 EP disclosed
CN-120053660-A Hydrophilic complex for preventing, preventing or treating microbial infection, preparation and application thereof 太阳雨林(北京)生物医药有限公司 2025-05-30 CN disclosed
CN-120053661-A Hydrophilic fatty acid complex for preventing, preventing or treating microbial infection, preparation and application thereof 太阳雨林(北京)生物医药有限公司 2025-05-30 CN disclosed
CN-119855607-A Carbon chain substance for regulating transmembrane transport and fluidity of cell membrane, preparation and application 太阳雨林(北京)生物医药有限公司 2025-04-18 CN disclosed
EP-4520348-A1 CARBON CHAIN SUBSTANCE FOR REGULATING TRANSMEMBRANE TRANSPORT AND FLUIDITY OF CELL MEMBRANES, AND PREPARATION AND USE THEREOF Sunforest (Beijing) Biopharma Ltd (CN) 2025-03-12 EP disclosed
WO-2023213310-A9 CARBON CHAIN SUBSTANCE FOR REGULATING TRANSMEMBRANE TRANSPORT AND FLUIDITY OF CELL MEMBRANES, AND PREPARATION AND USE THEREOF 太阳雨林(北京)生物医药有限公司 2025-02-20 WO disclosed
US-12216122-B2 Compositions and methods relating to detection, inhibition, and imaging of indoleamine 2,3-dioxygenase 1 (IDO1) REGENERON PHARMACEUTICALS, INC. (US) 2025-02-04 US disclosed
WO-2024227957-A2 METHOD OF DEPROTECTING AT LEAST ONE D-AMINO ACID AND/OR D-AMINO ACID DERIVATIVE PROTECTED FUNCTIONAL GROUP Martin-Luther-Universität Halle-Wittenberg (DE) 2024-11-07 WO disclosed
WO-2023213310-A1 CARBON CHAIN SUBSTANCE FOR REGULATING TRANSMEMBRANE TRANSPORT AND FLUIDITY OF CELL MEMBRANES, AND PREPARATION AND USE THEREOF 太阳雨林(北京)生物医药有限公司 2023-11-09 WO disclosed
WO-2003020900-A2 COMPOSITIONS AND METHODS RELATING TO BREAST SPECIFIC GENES AND PROTEINS DIADEXUS, INC. (US) 2003-03-13 WO disclosed
WO-2003020934-A1 COMPOSITIONS AND METHODS RELATING TO COLON SPECIFIC GENES AND PROTEINS DIADEXUS, INC. (US) 2003-03-13 WO disclosed
WO-2003020953-A2 COMPOSITIONS AND METHODS RELATING TO COLON SPECIFIC GENES AND PROTEINS DIADEXUS, INC. (US) 2003-03-13 WO disclosed
WO-2003020899-A2 COMPOSITIONS AND METHODS RELATING TO LUNG SPECIFIC GENES AND PROTEINS DIADEXUS, INC. (US) 2003-03-13 WO disclosed
WO-2003020901-A2 COMPOSITIONS AND METHODS RELATING TO PROSTATE SPECIFIC GENES AND PROTEINS DIADEXUS, INC. (US) 2003-03-13 WO disclosed
US-20030045553-A1 Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators ORTHO-MCNEIL PHARMACEUITCAL, INC. 2003-03-06 US disclosed
US-20020102610-A1 Automated identification of peptides OXFORD GLYCOSCIENCES (UK) LTD. (GB) 2002-08-01 US disclosed
US-20020055186-A1 Detection of peptides OXFORD GLYCOSCIENCES (UK) LTD. 2002-05-09 US disclosed
WO-2002025287-A2 DETECTION OF PEPTIDES OXFORD GLYCOSCIENCES (UK) LTD. (GB) 2002-03-28 WO disclosed
WO-2002021139-A2 AUTOMATED IDENTIFICATION OF PEPTIDES OXFORD GLYCOSCIENCES (UK) LTD. (GB) 2002-03-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12216122-B2 Compositions and methods relating to detection, inhibition, and imaging of indoleamine 2,3-dioxygenase 1 (IDO1) IDO1, IDO2, KYNU NOD1 42/4885CASP2 4329/4885GNAI3 703/4885
US-20030045553-A1 Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators GPR119, SLC2A4, PPARG NOD1 4063/4885CASP2 4747/4885GNAI3 1238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.